Clinical Trial Update: A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial evaluating DH001 tablets to prevent doxorubicin-induced cardiotoxicity in cancer patients; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmia
• Cancer
• Doxorubicin-induced Cardiomyopathy
• Heart Failure

Drugs mentioned

• DH001 tablets

Snippet

Sponsor: Monyan Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Cancer, Heart Failure | Phase 2 | Status: UNKNOWN